Venus Remedies Ltd Falls 12.90% Amid Sharp Volatility: 5 Key Events Shaping the Week

29 June 2026: New 52-Week and All-Time High Amid Strong Momentum

Venus Remedies Ltd began the week on a high note, hitting a new 52-week and all-time high of Rs.2,043.15. The stock surged 5.00% intraday, closing at Rs.1,966.50, supported by robust financial results and sustained investor confidence. This rally was driven by strong quarterly earnings, with profit after tax rising 126.19% to Rs.47.50 crore and net sales increasing 33.05% to Rs.259.40 crore. The company’s net-debt free status and expanding institutional participation further bolstered sentiment.

Technically, the stock traded above all key moving averages, signalling a strong bullish trend. The upper circuit was hit during the session, reflecting intense buying interest and unfilled demand. Despite the broader Sensex remaining flat, Venus Remedies outperformed its sector and the market, delivering a cumulative return of nearly 20% over the preceding four days.

30 June 2026: Sharp Reversal as Lower Circuit is Hit

The optimism was short-lived as Venus Remedies plunged 5.00% on 30 June, hitting its lower circuit at Rs.1,833.50 amid heavy selling pressure. This decline starkly contrasted with the Pharmaceuticals & Biotechnology sector’s 0.78% gain and the Sensex’s near-flat performance. The stock’s weighted average price skewed towards the lower band, indicating aggressive offloading by sellers and a lack of buyer support.

Trading volumes remained healthy at 43,713 shares, but delivery volumes dropped by 35.68%, signalling waning conviction among long-term holders. Despite the sharp fall, the stock maintained its position above key moving averages, suggesting that the longer-term uptrend was intact but under immediate pressure.

1 July 2026: Continued Selling Pressure Triggers Another Lower Circuit

On 1 July, Venus Remedies again hit the lower circuit limit, falling 5.00% to close at Rs.1,743.00. The stock opened sharply lower and traded near the day’s low throughout, reflecting panic selling and a lack of buy-side interest. The total traded volume was 38,287 shares, with delivery volumes declining further by 25.24%, underscoring reduced investor participation.

This three-day losing streak resulted in a cumulative loss of 10.53%, a stark underperformance relative to the sector’s modest gains and the Sensex’s 0.26% rise. The stock’s short-term technical indicators weakened, trading below its 5-day moving average, though longer-term averages remained supportive.

2 July 2026: Marginal Decline Amid Moderate Volumes

Venus Remedies continued its downward trajectory on 2 July, closing at Rs.1,765.55, down 0.52%. Trading volumes were moderate at 45,660 shares, with the stock still trading above its 20-day and longer moving averages, indicating some technical support. The Sensex gained 0.71% on the day, further emphasising the stock’s relative weakness.

Despite the decline, the stock’s technical indicators such as MACD and Bollinger Bands remained broadly positive on weekly and monthly charts, suggesting that the recent sell-off may be a short-term correction within a longer-term uptrend.

3 July 2026: Week Closes with Further Losses

The week ended with Venus Remedies closing at Rs.1,712.80, down 2.99% on the day and 12.90% for the week. Volume was relatively low at 25,870 shares, reflecting cautious investor sentiment. The Sensex rose 0.15%, underscoring the stock’s continued underperformance. The persistent selling pressure and declining delivery volumes highlight ongoing investor apprehension despite the company’s solid fundamentals and recent rating upgrades.

Key Takeaways

The week for Venus Remedies Ltd was characterised by extreme volatility, with a sharp reversal from a new 52-week high to multiple lower circuit hits. The stock’s 12.90% weekly decline starkly contrasts with the Sensex’s 1.31% gain, highlighting significant underperformance amid sector and market strength.

Strong quarterly financials and a net-debt free balance sheet underpin the company’s fundamentals, supported by a Mojo Score of 71.0 and a Buy grade. However, the intense selling pressure, declining delivery volumes, and panic-driven lower circuit hits indicate short-term investor caution and profit-booking.

Technical indicators remain mixed: while longer-term moving averages and momentum indicators suggest an underlying bullish trend, short-term weakness and volume patterns warrant close monitoring. The stock’s micro-cap status adds to its volatility and risk profile.

Investors should weigh the company’s solid fundamentals against the recent price weakness and market sentiment shifts, recognising the potential for continued volatility in the near term.

Conclusion

Venus Remedies Ltd’s week was a study in contrasts, beginning with a milestone all-time high and ending with a significant correction marked by circuit breaker events. The stock’s sharp 12.90% weekly fall amid a rising Sensex underscores the challenges micro-cap stocks face in volatile markets despite strong fundamentals.

While the company’s financial performance and technical positioning remain supportive, the recent selling pressure and reduced investor participation highlight the need for caution. The coming weeks will be critical in determining whether Venus Remedies can stabilise and resume its upward trajectory or if further consolidation is required.

Market participants should continue to monitor volume trends, sector developments, and company-specific news to better understand the evolving risk-reward profile of this micro-cap pharmaceutical stock.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →